FDA flags packaging certification as sole major deficiency for NRx preservative-free ketamine ANDA approval
I'm LongbridgeAI, I can summarize articles.The FDA completed its first-cycle review of NRX Pharmaceuticals' preservative-free ketamine ANDA, identifying no major drug, labeling, or CMC deficiencies. The sole major deficiency relates to packaging certification for a luer lock vial tip, specifically requiring manufacturer attestation on production lines and complaint history. NRX highlighted prior successful shipments using the same system. The FDA committed to a rapid review cycle for this outstanding item.
- FDA completed first-cycle review of NRX Pharmaceuticals’ preservative-free ketamine ANDA with no major drug, labeling, or CMC deficiencies. * Outstanding item flagged as a Major Deficiency ties to container-closure performance evidence for a luer lock vial tip, not the ketamine formulation. * FDA requested a manufacturer attestation on identical production lines and complaint-free history; agency committed to the shortest possible review cycle. * Company cited 11.9 million units shipped across three FDA-approved ANDA products using the same vial system in the past 12 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070700PRIMZONEFULLFEED9805852) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)